Please login to the form below

Not currently logged in

plaque psoriasis

This page shows the latest plaque psoriasis news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II

BMS already has a phase III programme called POETYK underway in patients with moderate to severe plaque psoriasis, and that includes a comparative arm against Celgene’s oral therapy Otezla (apremilast) ... which brought in $1.3bn in sales last year in

Latest news

More from news
Approximately 6 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Pre-registration (US) topical high potency steroid for moderate to severe plaque psoriasis.

  • 'Nothing about us without us' 'Nothing about us without us'

    Similarly, Novartis - which issued a patient declaration committing, among other things, to inviting patient input early on in their clinical trial process - recently invited people living with plaque psoriasis to attend

  • Deal Watch March 2017 Deal Watch March 2017

    Merck KGaA has partnered its product M1095 (ALX-0761), for plaque psoriasis, to Avillion.

  • Deal Watch July 2016 Deal Watch July 2016

    The product completed Phase 3 studies in moderate to severe plaque psoriasis in May 2016 and announced that the primary endpoints had been met. ... Acquisition. 78. Sun Pharma/ Almirall. Tildrakizumab (IL-23p19 inhibitor) - psoriasis. Licence.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...